Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1526083 | 0.79 | APP (0.40) | APPCA2 | |
| SCHEMBL18030587 | 0.77 | APP (0.33) | APPCA2 | |
| SCHEMBL18030513 | 0.77 | APP (0.39) | APPCA2 | |
| SCHEMBL18867838 | 0.77 | KDM4E (0.33) | — | |
| SCHEMBL20999586 | 0.77 | APP (0.36) | APPCA2 | |
| SCHEMBL18485037 | 0.76 | APP (0.38) | APPCA2 | |
| SCHEMBL22566305 | 0.76 | APP (0.38) | APPCA2 | |
| SCHEMBL24359860 | 0.74 | APP (0.35) | APPCA2 | |
| SCHEMBL22519814 | 0.74 | — | — | |
| SCHEMBL22556026 | 0.74 | APP (0.37) | APPCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358929-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-3558318-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230107642-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2020212755-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | WO | disclosed |
| US-20200087323-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
| EP-3558318-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | Cadent Therapeutics, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119374-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018119374-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS (US) | 2018-06-28 | — | — | WO | disclosed |
| US-9796735-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| WO-2009097578-A1 | OXIM DERIVATIVES AS HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807650-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | APP 2758/4885CA2 3134/4885 |
| US-20230107642-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | APP 4682/4885CA2 4037/4885 |
| US-11845761-B2 | Tricyclic pyridones and pyrimidones | KRAS, NRAS, HRAS | APP 4682/4885CA2 4037/4885 |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | APP 2758/4885CA2 3134/4885 |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | APP 2758/4885CA2 3134/4885 |
| US-12358929-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | APP 2758/4885CA2 3134/4885 |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | APP 4682/4885CA2 4037/4885 |
| US-20200087323-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | APP 2758/4885CA2 3134/4885 |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | APP 2758/4885CA2 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.